VCP R191Q

# Research Brief: VCP R191Q Variant ## Pathogenic Mechanisms The VCP R191Q variant represents a pathogenic mutation in valosin-containing protein (VCP), a critical AAA+ ATPase involved in cellular protein quality control and proteostasis. VCP functions through ATP binding and hydrolysis to regulate multiple cellular processes including aggresome assembly, autophagosome maturation, and ATP metabolism. The R191Q substitution occurs within the N-terminal domain of VCP, likely disrupting the protein's ability to properly execute its ATPase activity and interact with key cofactors including UBXN family proteins (UBXN2A, UBXN6, UBXN7) and NSFL1C. This mutation is specifically associated with inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD), a devastating multisystem proteinopathy. The pathogenic mechanism likely involves impaired protein degradation pathways, leading to toxic protein aggregation in muscle, bone, and neuronal tissues. The mutation's position suggests potential disruption of the protein's conformational dynamics required for substrate recognition and processing. ## Clinical Significance The R191Q variant is classified as pathogenic and represents one of several VCP mutations causing IBMPFD, a rare autosomal dominant condition with variable age of onset and phenotypic expression. Clinical manifestations include progressive muscle weakness (inclusion body myopathy), bone disease (Paget disease), and cognitive decline with behavioral changes (frontotemporal dementia). The establishment of baseline data collection protocols is critical for tracking disease progression and understanding phenotypic variability among R191Q carriers. This variant's pathogenicity underscores the essential role of VCP in maintaining cellular proteostasis across multiple tissue types, with mutation consequences manifesting through tissue-specific protein aggregate accumulation and cellular dysfunction. ## Therapeutic Landscape Current therapeutic development faces significant challenges, though aggregation hotspots have been identified at residues 265-269 (aggregation score: 0.80), providing potential targets for intervention. These aggregation-prone regions downstream of the R191Q mutation site may represent critical nucleation points for pathogenic protein accumulation. Therapeutic strategies could focus on: (1) small molecules that enhance VCP ATPase activity or restore proper protein-cofactor interactions, (2) peptide inhibitors targeting the 265-269 aggregation hotspot to prevent oligomerization, and (3) approaches to enhance compensatory proteostasis pathways. The identification of this aggregation hotspot opens opportunities for structure-based design of aggregation inhibitors or molecular chaperones that could prevent toxic protein accumulation. ## Research Directions Critical knowledge gaps require immediate attention: (1) detailed structural characterization of how R191Q affects VCP hexamer formation and ATPase cycling, (2) identification of early biomarkers for disease onset and progression in asymptomatic carriers, (3) development of patient-derived cellular models to test therapeutic candidates, and (4) establishment of natural history studies with standardized outcome measures. Understanding genotype-phenotype correlations across VCP mutations could reveal modifier genes and compensatory mechanisms. High-priority research should focus on developing aggregation inhibitors targeting the 265-269 hotspot and identifying combination therapies that address the multisystem nature of IBMPFD.